Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10862658 | 0.87 | MEN1 (0.38) | CD44MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL3789587 | 0.81 | ALDH1A1 (0.52) | CD44MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL111389 | 0.79 | — | — | |
| SCHEMBL2426196 | 0.79 | MEN1 (0.48) | CD44MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL3550151 | 0.79 | MEN1 (0.62) | CD44MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL9180527 | 0.78 | MEN1 (0.42) | CD44MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL30908373 | 0.78 | CD44 (0.52) | CD44MAPTCYP3A4TSHRPIK3CA | |
| SCHEMBL7463021 | 0.78 | CYP3A4 (0.59) | CD44MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL10423683 | 0.78 | CD44 (0.52) | CD44MAPTCYP3A4TSHRPIK3CA | |
| Hydrochloric Acid SCHEMBL8837519 | 0.77 | MEN1 (0.59) | MEN1KMT2AMAPTNPSR1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255101-A1 | Tetradentate Metal Complexes with Carbon Group Bridging Ligands | UNIV ARIZONA STATE (US) | 2023-08-10 | — | — | US | disclosed |
| CN-114502672-A | Coating composition | PRC-迪索托国际公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2020059048-A1 | SET COMPRISING MAIN AGENT AND CURING AGENT, WATER-RESISTANT MATERIAL, AND METHOD OF CONSTRUCTING SAME | 保土谷化学工業株式会社 | 2020-03-26 | — | — | WO | disclosed |
| US-9771372-B2 | Compounds useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2017-09-26 | — | — | US | disclosed |
| US-20170204098-A1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2017-07-20 | — | — | US | disclosed |
| EP-2991990-B1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2017-02-01 | — | — | EP | disclosed |
| EP-2991990-A1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | Active Biotech AB (SE) | 2016-03-09 | — | — | EP | disclosed |
| WO-2015177367-A1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2015-11-26 | — | — | WO | disclosed |
| US-7232912-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232912-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20060111322-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20050239855-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-6919461-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-0974576-B1 | Method of producing benzamide derivatives | MITSUI CHEMICALS INC (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-20030139463-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | REICH SIEGFRIED HEINZ (US) | 2003-07-24 | — | — | US | disclosed |
| US-6555539-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS | 2003-04-29 | — | — | US | disclosed |
| EP-1250326-A2 | INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE FOR MEDIATING OR INHIBITING CELL PROLIFERATION | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-23 | — | — | EP | disclosed |
| US-6320078-B1 | CONVERTING BENZOIC ACID DERIVATIVE INTO BENZOYLIMIDAZOLE DERIVATIVE, REACTING BENZOYLIMIDAZOLE DERIVATIVE WITH PHENYLENEDIAMINE DERIVATIVE TO PREPARE SELECTIVELY MONOACYLATED PHENYLENEDIAMINE DERIVATIVE | MITSUI CHEMICALS, INC. (JP) | 2001-11-20 | — | — | US | disclosed |
| WO-2001053268-A2 | INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE FOR MEDIATING OR INHIBITING CELL PROLIFERATION | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| EP-0974576-A2 | Method of producing benzamide derivatives | Mitsui Chemicals, Inc. (JP) | 2000-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204098-A1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | S100A9, S100A4, S100B | CD44 347/4885MEN1 345/4885KMT2A 4646/4885 |
| US-20050239855-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | CD44 1346/4885MEN1 3716/4885KMT2A 4636/4885 |
| US-20030139463-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | CD44 1346/4885MEN1 3716/4885KMT2A 4636/4885 |
| US-20230255101-A1 | Tetradentate Metal Complexes with Carbon Group Bridging Ligands | STAU1, POLR1G, CLTC | CD44 2912/4885MEN1 1371/4885KMT2A 4092/4885 |
| US-20060111322-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | MKI67, CCNI, CDK3 | CD44 633/4885MEN1 766/4885KMT2A 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.